Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Standardized Pollen Allergenic Extract [EPC]
Festuca Pratensis Pollen is a standardized allergenic extract used in the diagnosis and treatment of grass-pollen-induced allergic rhinitis and conjunctivitis. It belongs to the class of Standardized Pollen Allergenic Extracts and works by inducing immunological tolerance.
Name
Festuca Pratensis Pollen
Raw Name
FESTUCA PRATENSIS POLLEN
Category
Standardized Pollen Allergenic Extract [EPC]
Drug Count
22
Variant Count
24
Last Verified
February 17, 2026
About Festuca Pratensis Pollen
Festuca Pratensis Pollen is a standardized allergenic extract used in the diagnosis and treatment of grass-pollen-induced allergic rhinitis and conjunctivitis. It belongs to the class of Standardized Pollen Allergenic Extracts and works by inducing immunological tolerance.
Detailed information about Festuca Pratensis Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Festuca Pratensis Pollen.
Festuca Pratensis Pollen, commonly known as Meadow Fescue pollen, is a biological substance derived from the perennial grass species Festuca pratensis. In the clinical setting, this pollen is processed into allergenic extracts used for both the diagnosis (via skin prick testing) and the treatment (via allergen immunotherapy) of Type I hypersensitivity reactions. Festuca Pratensis Pollen belongs to a class of drugs called Standardized Pollen Allergenic Extracts [EPC]. These extracts are fundamental tools for allergists and immunologists in managing patients who suffer from seasonal allergic rhinitis (hay fever), allergic conjunctivitis, and in some cases, allergic asthma triggered by grass pollens.
Historically, the use of pollen extracts dates back to the early 20th century, but modern extracts are now highly refined and standardized. The FDA regulates these products as biologics under the Center for Biologics Evaluation and Research (CBER). While many grass pollens are available as non-standardized extracts, Festuca Pratensis is often included in standardized mixtures where the potency is measured in Bioequivalent Allergen Units (BAU) or Allergen Units (AU). This standardization ensures that each dose delivered to a patient has a consistent level of biological activity, which is crucial for both safety and efficacy during the long-term desensitization process.
Festuca Pratensis Pollen works through a complex process known as allergen immunotherapy (AIT). Unlike symptomatic treatments like antihistamines or corticosteroids, which merely suppress the inflammatory response, AIT aims to modify the underlying disease process. When a patient is allergic to Meadow Fescue, their immune system incorrectly identifies the pollen proteins as dangerous threats, leading to the production of Immunoglobulin E (IgE) antibodies. These IgE antibodies bind to mast cells and basophils. Upon subsequent exposure to the pollen, the allergen cross-links the IgE, causing the cells to degranulate and release inflammatory mediators like histamine, leukotrienes, and prostaglandins.
At the molecular level, regular administration of Festuca Pratensis Pollen extract induces a state of immunological tolerance. This is achieved through several mechanisms:
Because Festuca Pratensis Pollen is a complex mixture of proteins and glycoproteins administered immunologically, its pharmacokinetic profile differs significantly from traditional small-molecule drugs.
Festuca Pratensis Pollen extracts are FDA-approved for the following indications:
Festuca Pratensis Pollen is available in several specialized formulations:
> Important: Only your healthcare provider can determine if Festuca Pratensis Pollen is right for your specific condition. Immunotherapy must be initiated and monitored by a physician trained in allergy and immunology.
Dosage for Festuca Pratensis Pollen is highly individualized and is divided into two distinct phases: the Build-up Phase and the Maintenance Phase.
During this phase, the patient receives increasing doses of the pollen extract. For Subcutaneous Immunotherapy (SCIT), injections are typically given 1 to 3 times per week. The starting dose is usually 1,000 to 10,000 times weaker than the final maintenance dose. The concentration is gradually increased over 3 to 6 months based on the patient's local and systemic tolerance.
Once the target dose (maintenance dose) is reached, the interval between injections is increased. Maintenance injections are typically administered every 2 to 4 weeks. The goal is to maintain the highest dose that the patient can tolerate without significant side effects. This phase generally lasts for 3 to 5 years to ensure long-lasting desensitization.
Festuca Pratensis Pollen extracts are generally approved for use in children, typically starting at age 5. The dosing schedule for children follows the same escalation principles as adult dosing, though the physician may choose a more conservative build-up schedule depending on the child's sensitivity and history of asthma.
No specific dosage adjustments are required for patients with renal impairment, as the allergenic proteins are not cleared by the kidneys in a manner that would lead to systemic toxicity.
No dosage adjustments are necessary for patients with hepatic impairment.
Clinical studies for allergenic extracts often do not include sufficient numbers of subjects aged 65 and over. Healthcare providers must evaluate the cardiovascular status of elderly patients, as they may be less able to tolerate the physiological stress of a systemic allergic reaction or the administration of epinephrine if an emergency occurs.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to maintain safety. If a maintenance dose is missed by more than a week or two, the allergist will usually reduce the dose for the next injection and then gradually build back up. Never attempt to 'double up' on doses to make up for a missed one.
An overdose of Festuca Pratensis Pollen (receiving a dose higher than the patient's current tolerance level) carries a high risk of systemic allergic reactions or anaphylaxis. Signs of overdose include generalized itching, hives, swelling of the throat, wheezing, and a drop in blood pressure. In the event of an overdose, emergency protocols for anaphylaxis, including the administration of epinephrine, must be followed immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or the timing of your injections without medical guidance.
The most common side effects associated with Festuca Pratensis Pollen immunotherapy are local reactions at the site of administration.
> Warning: Stop taking Festuca Pratensis Pollen and call your doctor or emergency services immediately if you experience any of these symptoms of anaphylaxis.
There are no known long-term 'toxic' side effects of Festuca Pratensis Pollen extracts in the traditional sense (such as organ damage). The primary long-term consideration is the potential for the patient to become increasingly sensitive to the extract, requiring a downward adjustment of the dose. In rare cases, chronic local reactions can lead to minor subcutaneous scarring or 'dimpling' at the injection site over several years of therapy.
Most standardized grass pollen extracts carry a Black Box Warning regarding the risk of severe, life-threatening anaphylaxis. The warning states that:
Report any unusual symptoms to your healthcare provider, even if they seem minor at first.
Festuca Pratensis Pollen is a potent biological agent. It should only be used by patients with a confirmed diagnosis of grass pollen allergy through skin testing or in vitro (blood) testing. It is not a treatment for non-allergic rhinitis or viral infections.
No FDA black box warnings for Festuca Pratensis Pollen exist as a single-ingredient generic label, but all commercial extracts of this class (Standardized Pollen Allergenic Extracts) carry a class-wide warning regarding anaphylaxis. This warning emphasizes that the product can cause life-threatening allergic reactions. Treatment should be withheld if the patient is experiencing an acute asthma flare or a significant infection. Patients must be informed that they may need to use an epinephrine autoinjector if a reaction occurs after they have left the clinic.
While there are no standard blood tests (like liver or kidney panels) required for Festuca Pratensis Pollen, the following monitoring is essential:
Festuca Pratensis Pollen generally does not affect the ability to drive. However, if a patient experiences a systemic reaction involving dizziness or receives emergency medication (like antihistamines that cause drowsiness or epinephrine), they should not drive until symptoms have fully resolved and they are cleared by a professional.
There is no direct chemical interaction between Festuca Pratensis Pollen and alcohol. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption and potentially worsen an allergic reaction. It is advisable to avoid alcohol for several hours before and after an injection.
Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. If a patient experiences a severe systemic reaction, the healthcare provider may decide to discontinue the therapy permanently. There is no 'withdrawal syndrome' associated with stopping pollen extracts, but the patient's allergy symptoms may eventually return if the course of treatment was too short.
> Important: Discuss all your medical conditions with your healthcare provider before starting Festuca Pratensis Pollen.
There are no known direct food interactions with Festuca Pratensis Pollen. However, patients with 'Oral Allergy Syndrome' (Pollen-Food Allergy Syndrome) may find that their sensitivity to certain fruits (like melons or oranges, which can cross-react with grass pollens) increases during the build-up phase of immunotherapy.
There is limited data on herbal interactions. However, supplements that affect the immune system (such as high-dose echinacea or astragalus) should be discussed with an allergist, as they could theoretically interfere with the goal of inducing immunological tolerance.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Festuca Pratensis Pollen contains proteins that are highly cross-reactive with other members of the Pooideae subfamily, including Timothy grass (Phleum pratense), Orchard grass (Dactylis glomerata), and Kentucky Bluegrass (Poa pratensis). Patients allergic to one are almost certainly allergic to the others. This is why many treatment vials contain a 'Grass Mix' rather than just Meadow Fescue alone.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Festuca Pratensis Pollen.
Festuca Pratensis Pollen is classified as Pregnancy Category C (under the old FDA system). There are no adequate and well-controlled studies in pregnant women. The primary risk to the fetus is maternal anaphylaxis, which can lead to uterine contractions, placental abruption, or fetal hypoxia (lack of oxygen).
It is not known whether the allergenic proteins or the resulting antibodies (IgG4) are excreted in human milk. However, because these are large proteins that would likely be digested in the infant's stomach, the risk to a nursing infant is considered negligible. The decision to continue AIT while breastfeeding should be made based on the mother's clinical need.
Festuca Pratensis Pollen is safe and effective for use in children as young as 5 years old. Research indicates that AIT in children can not only reduce current symptoms but also significantly reduce the risk of developing asthma later in life (the 'allergic march'). Special care must be taken to ensure the child can communicate early symptoms of a reaction, such as an itchy throat or 'feeling funny.'
Use in patients over 65 requires caution. Older adults are more likely to have comorbid cardiovascular conditions (hypertension, CAD) that make them more vulnerable to the effects of a systemic reaction or the epinephrine used to treat it. Renal and hepatic changes do not affect the dosing of these biological extracts.
There are no specific studies on patients with renal impairment. However, since the clearance of proteins does not rely on glomerular filtration, no dose adjustments are anticipated. Dialysis does not clear allergenic extracts from the system.
No dosage adjustments are required for patients with liver disease. The metabolic processing of these allergens occurs within the immune system's cells (macrophages and dendritic cells) rather than through the cytochrome P450 system in the liver.
> Important: Special populations require individualized medical assessment by an allergy specialist.
Festuca Pratensis Pollen acts as an immunomodulator. The primary allergens in Meadow Fescue (such as the Group 1 and Group 5 grass allergens) are recognized by the immune system's antigen-presenting cells (APCs). In an allergic individual, these APCs normally present the allergen to Th2 cells. Immunotherapy changes this paradigm by favoring the production of T-regulatory (Treg) cells. These Treg cells secrete Interleukin-10 (IL-10), which has several effects: it suppresses Th2-induced inflammation, inhibits mast cell degranulation, and induces B-cells to switch from producing IgE to producing IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody, preventing the allergen from reaching the IgE bound to mast cells.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Local/Lymphatic uptake) |
| Protein Binding | N/A |
| Half-life | Proteins degraded within hours/days |
| Tmax | N/A |
| Metabolism | Proteolytic degradation in APCs |
| Excretion | Not renally excreted |
Festuca Pratensis Pollen is classified as a Standardized Pollen Allergenic Extract. It is therapeutically grouped with other grass pollen extracts like Timothy (Phleum pratense) and Orchard grass (Dactylis glomerata).
Common questions about Festuca Pratensis Pollen
Festuca Pratensis Pollen, or Meadow Fescue extract, is primarily used for the diagnosis and treatment of seasonal grass allergies. In a clinical setting, it is used in skin prick tests to identify if a patient has a specific allergy to this grass. For treatment, it is used in allergen immunotherapy (allergy shots or drops) to desensitize the immune system over time. This helps reduce symptoms like sneezing, runny nose, and itchy eyes during the hay fever season. It is specifically indicated for patients who do not get enough relief from standard allergy medications.
The most frequent side effects are local reactions at the site where the extract was administered. For those receiving injections (SCIT), this usually involves redness, itching, and swelling of the arm, which can occur immediately or several hours later. For those using sublingual drops (SLIT), common side effects include an itchy mouth or throat and mild swelling of the tongue. These reactions are generally a sign that the immune system is interacting with the allergen. While common, they should always be reported to your doctor to ensure the dose is still appropriate.
While there is no direct chemical interaction between the pollen extract and alcohol, it is generally recommended to avoid alcohol for several hours before and after your allergy treatment. Alcohol can cause blood vessels to dilate (vasodilation), which might increase the speed at which the allergen is absorbed into your bloodstream. This could theoretically increase the risk of a systemic allergic reaction or make a reaction more severe. Additionally, alcohol can make it harder for you to notice early symptoms of an allergic reaction. Always follow the specific safety guidelines provided by your allergist.
Allergen immunotherapy with Festuca Pratensis Pollen is usually not started during pregnancy because of the risk of anaphylaxis, which could harm the fetus. However, if a woman is already on a stable maintenance dose and becomes pregnant, many allergists allow the treatment to continue since the risk of a severe reaction is much lower at that stage. The decision is based on a careful balance between the mother's need for allergy control and the potential risks. You must inform your healthcare provider immediately if you become pregnant while receiving this treatment. It is never recommended to increase the dose during pregnancy.
Immunotherapy is a long-term treatment process and does not provide immediate relief like an antihistamine. Most patients begin to notice a reduction in their allergy symptoms after they reach their maintenance dose, which usually takes 3 to 6 months of weekly injections. Significant improvement is typically seen during the first grass pollen season after reaching maintenance. For the best and most lasting results, the treatment is usually continued for 3 to 5 years. This long duration is necessary to 'retrain' the immune system permanently.
Yes, you can stop taking the pollen extract suddenly without experiencing withdrawal symptoms, as it is not an addictive or physiologically dependent medication. However, stopping the treatment prematurely, especially before the 3-year mark, significantly increases the chance that your allergy symptoms will return. If you stop during the build-up phase, you will lose any progress made toward desensitization. If you need to stop due to side effects or other concerns, always discuss it with your allergist first. They may be able to adjust the dose or schedule rather than stopping entirely.
If you miss a dose of your allergy shots or drops, you should contact your allergist's office for instructions. Do not attempt to take an extra dose to catch up. The safety of immunotherapy depends on a specific schedule; if too much time passes between doses, your sensitivity to the allergen may increase. Depending on how many days or weeks have passed, your doctor may need to repeat the last dose or even reduce the dose for your next visit to ensure you don't have a reaction. Consistency is key to both the safety and success of the treatment.
There is no clinical evidence to suggest that Festuca Pratensis Pollen or any other allergenic extracts cause weight gain. Unlike oral corticosteroids, which are sometimes used for severe allergies and are known to cause weight changes, immunotherapy works on the immune system through protein interaction. The amount of protein in each dose is microscopic and does not affect metabolism or appetite. If you experience weight changes while on this treatment, it is likely due to other factors or medications. You should discuss any concerns about weight with your primary care physician.
Festuca Pratensis Pollen can be taken with most common medications, but there are some critical exceptions. You must tell your doctor if you are taking beta-blockers, as these can make an allergic reaction much more dangerous and difficult to treat. ACE inhibitors and certain antidepressants may also interact with how your body handles a severe reaction. Most standard allergy medications like Claritin, Flonase, or Singulair are safe and often encouraged to be used alongside immunotherapy to manage symptoms during the build-up phase. Always provide your allergist with a complete list of your current medications.
Festuca Pratensis Pollen is a biological product, so the term 'generic' is not used in the same way as it is for chemical drugs like ibuprofen. Instead, it is available as various 'standardized extracts' produced by different biological laboratories. While the active ingredient—the Meadow Fescue pollen proteins—is the same, different brands may have slightly different concentrations or stabilizers. In the United States, these are often sold under the labels of major allergenic extract manufacturers. Your allergist will select a high-quality, FDA-regulated extract that meets standardization requirements.